Close Menu

chlamydia

Roche said this week that its Cobas CT/NG test for Chlamydia trachomatis and Neisseria gonorrhoeae infections has received 510(k) clearance from the US Food and Drug Administration.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Roche today announced its cobas CT/NG Test for Chlamydia trachomatis and Neisseria gonorrhoeae infections has received 510(k) clearance from the US Food and Drug Administration.

Gen-Probe said this week that Health Canada has granted the company a medical device license for Panther, Gen-Probe's fully automated and integrated molecular testing platform.

Life Tech's 7500 Fast Dx and 3500 Dx Series Genetic Analyzer approved in Japan; Roche files Cobas CT/NG test with FDA.

The platform will combine immiscible phase filtration sample prep with automated amplification and detection, and is expected to have initial applications in point-of-care HIV testing in remote and resource-poor areas of the world. The company also sees the platform being used for decentralized molecular testing in more developed countries.

As part of the deal, FIND will have rights to sell the HIV test, as well as Cepheid's Xpert chlamydia and gonorrhea tests, which will be sold at a discount to the public and the not-for-profit sector in some countries.

Pages

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.